Safe and Efficacious Use of Low-Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia.

ABSTRACT:

Background

Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m² weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This study evaluates lower-dose Rituximab with dexamethasone in postpubertal pediatric ITP patients.

Methods

Patients treated with 100 mg weekly Rituximab for 4 weeks alongside dexamethasone at 10 mg/m² on days 1-5 and 21-25 were assessed for response and safety.

Results

Of the 10 patients treated, six responded completely, one partially and three showed no response. Four responders maintained their response over 2 years. One Rituximab-related infusion reaction and on

SUBMITTER: Darlow J 

PROVIDER: S-EPMC12044411 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature